Both in vitro and in vivo experiments using xenografted melanoma tumor models demonstrated that this nanoconjugate could effectively enhance and activate T cells within BMDCs, leading to an improved CD4+ and CD8+ antigen expression following intravenous injection as opposed to intratumoral injection (Figure 3e,f). Here, CD8A is linked to neoplasm.